Tevogen Bio Holdings

Tevogen Bio Holdings Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Warren, New Jersey and currently employs 18 full-time employees. The company went IPO on 2021-11-04. Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy company. The firm is harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs), to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the unmet needs of patient populations. Its first product candidate, TVGN 489, has developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic lingering symptoms of the disease. Its TVGN 601 is being developed for multiple sclerosis (MS), and its TVGN 930 is being developed for EBV-associated lymphomas.